Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

C-130

Supelco

Cortisone solution

100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C21H28O5
Numéro CAS:
53-06-5
Poids moléculaire :
360.44
Numéro CE :
200-659-6
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Niveau de qualité

300

Forme

liquid

Caractéristiques

(Snap-N-Spike®)

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

Concentration

100 μg/mL in methanol

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

clinical testing
clinical testing

Format

single component solution

Température de stockage

−20°C

InChI

1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-15,18,22,26H,3-8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1

Clé InChI

MFYSYFVPBJMHGN-ZPOLXVRWSA-N

Description générale

Cortisone is a corticosteroid produced in the adrenal glands. Cortisone is administered for short term pain relief and to reduce swelling from inflammation. This Certified Spiking Solution® is applicable in LC-MS/MS applications for endocrinology, clinical chemistry and neonatal screening.

Application


  • Measurement of free urinary cortisol and cortisone: A study demonstrated the use of cortisone solutions in a method for the precise measurement of free urinary cortisol and cortisone using liquid chromatography and tandem mass spectrometry, crucial for diagnosing and managing endocrine disorders (Vieira et al., 2005).


Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

A-096

Aldosterone solution, 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

C-106

Cortisol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

C-113

Cortisol-D4 (9,11,12, 12-D4) solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

C-117

Corticosterone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

D-061

11-Deoxycortisol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

D-062

21-Deoxycortisol solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

D-076

21-Deoxycortisol-d8 (2,2,4,6,6,21,21,21-d8), 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

D-078

11-Deoxycortisol-D5 (2,2,4,6,6-D5), 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

D-085

Dexamethasone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

H-085

17α-Hydroxyprogesterone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

H-096

17α-Hydroxyprogesterone-d8 (2,2,4,6,6,21,21,21-d8), 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

H-100

17α-Hydroxyprogesterone-2,3,4-13C3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-069

Progesterone solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

P-070

Progesterone-D9 solution, 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

H-151

6alpha-Hydroxyhydrocortisone solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

C-160

Cortisone-13C3 solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

C-159

Corticosterone-13C3 solution, 10 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

P-123

Prednisolone-13C3 solution, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

P-124

Prednisone-13C3 solution, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

Pictogrammes

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organes cibles

Eyes,Central nervous system

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

49.5 °F - closed cup

Point d'éclair (°C)

9.7 °C - closed cup

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Hanns Kaiser
Wiener klinische Wochenschrift, 115(1-2), 6-21 (2003-03-28)
Five decades of experimental and clinical experience have changed corticoid therapy thoroughly. Corticoides have two modes of action. The first is a genomic effect through which anti-inflammatory proteins are formed which inhibit pro-inflammatory cytokines. This effect is initiated even by
[From classical corticotherapy to cortisone loading].
J Arlet
Annales de medecine interne, 145 Suppl 2, 5-10 (1994-06-01)
[50 years cortisone treatment--what has changed?].
H Kaiser
Fortschritte der Medizin, 116(26), 20-22 (1998-11-17)
M Malaguarnera et al.
Pharmacotherapy, 17(5), 998-1005 (1997-11-05)
Over the last 30 years many approaches have been adopted to treat chronic hepatitis. We conducted a meta-analysis to assess the efficacy of various types of treatments. We selected 4 studies of cortisone in chronic hepatitis B; 21 trials of
I Uttner et al.
Der Nervenarzt, 77(6), 647-648 (2005-11-12)
Treatment with high-dose corticosteroids over 3-5 days reduces the duration and severity of relapses in patients with multiple sclerosis. Since the benefit of this treatment appears to be dose-dependent, application of ultrahigh steroid doses becomes important. On the other hand
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique